

Figure 1. Original (**1**) and revised (**2**) structures of alkaloid 205 B, and the structure of its antipode, **3**.

asymmetric centers in its compact, fourteen-carbon-atom frame; however, no synthesis of this unique alkaloid has been reported, and its absolute stereochemistry is still unknown.

As part of a program directed at studying the synthesis of biologically active alkaloids,^[5] we report here the first total synthesis of **3** (see Figure 1), the antipode of natural 205 B, and the determination of the absolute stereochemistry of natural 205 B.


The synthesis began with enaminoester **4**,^[6] which was treated with lithium dimethylcuprate to give adduct **5** as a single isomer (Scheme 1).^[7] The oxazolizinone ring was constructed in a two-step sequence to provide **6**, which was transformed into the desired cyclic carbamate **8** via ester **7** by using the protocol developed by Matsumura et al.^[8]

Alkaloid Total Synthesis

Total Synthesis of the Antipode of Alkaloid 205 B**

Naoki Toyooka,* Ayako Fukutome, Hiroyuki Shinoda, and Hideo Nemoto*

A remarkably diverse array of biologically active alkaloids, for example, blockers of neuromuscular-type, ganglionic-type, and nicotinic receptor channels, occurs in amphibian skin, and over 500 alkaloids have been isolated to date.^[1] The structural diversity and pharmacological activity associated with these alkaloids have stimulated research in numerous synthetic groups.^[2] Alkaloid 205 B, one of the compounds isolated from skin extracts of the Panamanian frog *Dendrobates pumilio*, possesses an unusual and unique 8b-azaacenaphthylene ring system (Figure 1). The structure of alkaloid 205 B was first reported to be **1**,^[3] and recently revised to be **2** based upon FTIR, NMR, and MS data.^[4] This alkaloid contains five



Scheme 1. Synthesis of enaminoester **8**. Reagents and conditions: a) $(\text{Me})_2\text{CuLi}$, Et_2O , -78 to -30°C (98%); b) Lithium triethylborohydride, THF, 0°C (92%); c) NaH, THF, 0°C (99%); d) TBAF, THF, 0°C –RT (99%); e) 1. Swern oxidation, -78°C to 0°C , 2. NaClO_2 , NaH_2PO_4 , $t\text{BuOH}/\text{H}_2\text{O}$, 3. CH_2N_2 , EtOAc (86% over 3 steps); f) LiHMDS, PhSSPh, THF, -78 – 0°C (99%); g) *m*CPBA, 2,6-lutidine, CH_2Cl_2 , RT (85%). LiHMDS = lithium bis(trimethylsilyl)amide, *m*CPBA = *meta*-chloroperbenzoic acid, RT = room temperature, TBAF = tetrabutylammonium fluoride, X = *tert*-butyldiphenylsilyl.


The second and key Michael reaction of **8** with in situ generated lithium dimethylcuprate proceeded smoothly to afford adduct **9**, again as a single isomer (Scheme 2). The stereochemistry of **9** was confirmed by the NOE interactions indicated. The observed stereoselectivity of the Michael reaction of **8** can be explained by the stereoelectronic effect^[9] illustrated in Figure 2.

An Arndt–Eistert sequence was used for carbon-chain extension of **9** to give the homologated ester **10**, which was transformed into ketone **11** by reaction with Weinreb's amide (Scheme 3).^[10] Acid-catalyzed protection of the carbonyl group in **11** with ethylene glycol followed by hydrolysis of the oxazolidinone ring with base and protection of the

[*] Dr. N. Toyooka, Prof. Dr. H. Nemoto, A. Fukutome, Dr. H. Shinoda
Faculty of Pharmaceutical Sciences
Toyama Medical and Pharmaceutical University
Sugitani 2630, Toyama 930-0194 (Japan)
Fax: (+81) 76-434-4656
E-mail: toyooka@ms.toyama-mpu.ac.jp
nemotoh@ms.toyama-mpu.ac.jp

[**] We thank Professors Shigetoshi Kadota and Yasuhiro Tezuka for recording the NOE spectra of **14**.

Supporting information for this article is available on the WWW under <http://www.angewandte.org> or from the author.



Scheme 2. Synthesis of tetrasubstituted piperidine **9**.





Figure 2. Stereochemical course of the Michael reaction of the enamine **8**.



Scheme 3. Synthesis of compound **14** with the tricyclic core. Reagents and conditions: a) 1. LiOH, MeOH/H₂O, reflux, 2. ClCO₂Et, Et₃N, THF, 0°C, 3. CH₂N₂, Et₂O, 4. PhCO₂Ag, Et₃N, MeOH, RT (71% over 4 steps); b) 1. LiOH, MeOH/H₂O, reflux, 2. 1,1'-carbonyldiimidazole, THF, RT, 3. Et₃N, (MeO)MeNH·HCl, THF, RT (98% over 2 steps); c) MeMgBr, THF, 0°C to RT (73%); d) ethylene glycol, *p*TsOH, benzene, reflux (86%); e) 1. 2 M KOH in *i*PrOH, 120°C in a sealed tube, 2. Boc₂O, NaOH, dioxane/H₂O (74% over 2 steps); f) Swern oxidation, −78°C to 0°C; g) (EtO)₂P(O)CH₂CO₂Et, NaH, THF (74% over 2 steps); h) 1. 10% Pd/C, H₂, EtOAc, 2. DIBAL, CH₂Cl₂, −78°C; i) *p*TsOH, benzene/acetone, reflux (**14**; 62%, **15**; 15% over 3 steps); j) *p*TsOH, acetone, reflux (80%). Boc = *tert*-butoxycarbonyl, DIBAL = diisobutylaluminum hydride, *p*TsOH = *para*-toluenesulfonic acid.

resulting amine with Boc₂O provided alcohol **12** in 74% overall yield. Swern oxidation of **12** and Wittig–Horner reaction of the resulting aldehyde afforded the α,β -unsaturated ester **13**. Hydrogenation of **13** and reduction of the resulting ester with DIBAL followed by treatment with *p*TsOH in refluxing benzene/acetone provided the key

tricyclic compound **14** in 62% overall yield along with acetal **15** (15%), which was transformed into **14** by treatment with acid.

The stereochemistry at the newly formed position in **14** was confirmed by the NOE (2%) between H_{2a} and H_{5a}, and the stereoselectivity of the acid-catalyzed intramolecular Mannich-type cyclization is rationalized as depicted in Figure 3.





Figure 3. Stereochemical course of intramolecular Mannich-type cyclization reaction of **13** and the stereochemistry of **14**.


With the requisite tricyclic core **14** in hand, we next focused our attention on the final step for the completion of total synthesis of alkaloid 205B. First we examined the formation of the alkene unit by using triflate **16**. Thus treatment of **14** with chiral lithium amide base followed by Comins's triflating agent^[11] provided triflate **16** in 54% yield (Scheme 4). The structure of **16** was confirmed by the H,H COSY experiment and the coupling constant between H_{2a} and



Scheme 4. Attempted synthesis of **3** via triflate **16**. Reagents and conditions: a) 1. *R*-(*R**,*R**)-(+)-bis(α -methylbenzyl)amine, *n*BuLi, THF, 2. [*N,N*-bis(trifluoromethylsulfonyl)amino]-5-chloropyridine (Comins's reagent), −78 to −40°C (54%); b) [Pd(Ph₃P)₄], Me₃Al, ClCH₂CH₂Cl, 70°C; c) (Me)₂CuLi, THF, 0°C.

H₃. The cross-coupling reaction of **16** with trimethylaluminum in the presence of catalytic amounts of [Pd(Ph₃P)₄]^[12] afforded a complex mixture and no desired compound was isolated. The coupling reaction with lithium dimethylcuprate^[13] resulted in the complete recovery of starting material.

Thus, we were forced to introduce the C–C double bond by using the *exo*-alkene **17**. Wittig reaction of **14** afforded **17** in good yield (Scheme 5). Brief calculations (B3LYP method in Gaussian98, 6-31 + G** basis set) revealed that the desired isomer **3** is lower in energy than the other isomer **18**.^[14] Thus, the acid-catalyzed isomerization of **17** provided the isomeric products in a ratio of 6.5:1 (from crude NMR), and the major isomer **3** was isolated in 63% yield. The spectroscopic data (¹H and ¹³C NMR, IR, MS) of **3** ([α]_D²⁶ = +8.1) were identical with those of the natural product ([α]_D = −8.5), and the absolute stereochemistry was determined unambiguously to be 2*aR*,5*aR*,6*S*,8*S*,8*aR* by comparison of the optical rotations.



Scheme 5. Completion of the total synthesis of **3**. Reagents and conditions: a) $\text{MeP}^+\text{Ph}_3\text{I}^-$, $n\text{BuLi}$, THF, 0°C to RT (84%); b) $p\text{TsOH}$, benzene, reflux (63%).

In summary, we have demonstrated the first enantioselective total synthesis of the antipode **3** of the structurally unique alkaloid 205B. The key step in this synthesis is the stereocontrolled Micheal-type conjugate addition reaction of the enaminoester **8** to form the 2,3,5,6-tetrasubstituted piperidine ring system in **9**. Furthermore, we determined the absolute stereochemistry of the natural product to be $2aR, 5aR, 6S, 8S, 8aR$.

Received: May 15, 2003 [Z51906]

Keywords: alkaloids · Michael addition · natural products · nitrogen heterocycles · stereoelectronic effects

- [9] R. W. Hoffmann, *Chem. Rev.* **1989**, *89*, 1841–1873.
- [10] S. Nahm, S. M. Weinreb, *Tetrahedron Lett.* **1981**, *22*, 3815–3818.
- [11] D. L. Comins, A. Dehghani, *Tetrahedron Lett.* **1992**, *33*, 6299–6302.
- [12] K. Takai, M. Sato, K. Oshima, H. Nozaki, *Bull. Chem. Soc. Jpn.* **1984**, *57*, 108–115.
- [13] J. E. McMurry, W. J. Scott, *Tetrahedron Lett.* **1980**, *21*, 4313–4316.
- [14] Calculations were performed by using the B3LYP method in Gaussian98 with the 6-31 + G** basis set. The desired isomer **3** is more stable than isomer **18** by $2.01 \text{ kcal mol}^{-1}$.
- [1] J. W. Daly, H. M. Garraffo, T. F. Spande in *Alkaloids: Chemical and Biological Perspective, Vol. 13* (Ed.: S. W. Pelletier), Pergamon, New York, **1999**, pp. 1–161; J. W. Daly in *The Alkaloids, Vol. 50* (Ed.: G. A. Cordell), Academic Press, New York, **1998**, pp. 141–169.
- [2] C. J. Smith, A. B. Holmes, N. J. Press, *Chem. Commun.* **2002**, 1214–1215; S. Aoyagi, S. Hirashima, K. Saito, C. Kibayashi, *J. Org. Chem.* **2002**, *67*, 5517–5526; A. Wroblewski, K. Sahasrabudhe, J. Aubé, *J. Am. Chem. Soc.* **2002**, *124*, 9974–9975; F. A. Davis, B. Chao, A. Rao, *Org. Lett.* **2001**, *3*, 3169–3171; G. Kim, S. Jung, W.-j. Kim, *Org. Lett.* **2001**, *3*, 2985–2987; C.-H. Tan, A. B. Holmes, *Chem. Eur. J.* **2001**, *7*, 1845–1854; D. L. Comins, S. Huang, C. L. McArdle, C. L. Ingalls, *Org. Lett.* **2001**, *3*, 469–471; L.-L. Wei, R. P. Hsung, H. M. Sklenicka, A. I. Gerasyuto, *Angew. Chem.* **2001**, *113*, 1564–1566; *Angew. Chem. Int. Ed.* **2001**, *40*, 1516–1518; D. Enders, C. Thiebes, *Synlett* **2000**, 1745–1748; P. Michel, A. Rassat, J. W. Daly, T. F. Spande, *J. Org. Chem.* **2000**, *65*, 8908–8918; G. M. Williams, S. D. Roughley, J. D. Davies, A. B. Holmes, J. P. Adams, *J. Am. Chem. Soc.* **1999**, *121*, 4900–4901; W. H. Pearson, H. Suga, *J. Org. Chem.* **1998**, *63*, 9910–9918; D. L. Comins, D. H. LaMunyon, X. H. Chen, *J. Org. Chem.* **1997**, *62*, 8182–8187, and references therein.
- [3] T. Tokuyama, N. Nishimori, A. Shimada, M. W. Edwards, J. W. Daly, *Tetrahedron* **1987**, *43*, 643–657.
- [4] T. Tokuyama, H. M. Garraffo, T. F. Spande, J. W. Daly, *An. Asoc. Quim. Argent.* **1998**, *86*, 291–298.
- [5] N. Toyooka, H. Nemoto, *Drugs Future* **2002**, *27*, 143–158.
- [6] N. Toyooka, A. Fukutome, H. Nemoto, J. W. Daly, T. F. Spande, H. M. Garraffo, T. Kaneko, *Org. Lett.* **2002**, *4*, 1715–1718; N. Toyooka, M. Okumura, H. Nemoto, *J. Org. Chem.* **2002**, *67*, 6078–6081.
- [7] The stereoselectivity of the Micheal-type conjugate addition reaction of **4** to give **5** was controlled by $A^{(1,3)}$ strain and stereoelectronic effect; see: T. Momose, N. Toyooka, *J. Org. Chem.* **1994**, *59*, 943–945; N. Toyooka, K. Tanaka, T. Momose, J. W. Daly, H. M. Garraffo, *Tetrahedron* **1997**, *53*, 9553–9574.
- [8] Y. Matsumura, M. Inoue, Y. Nakamura, I. L. Talib, T. Maki, O. Onomura, *Tetrahedron Lett.* **2000**, *41*, 4619–4622.